Cover Image
Market Research Report
Product code 
1045789

Pharmacogenomics Services Market - A Global and Regional Analysis: Focus on Service, Technology, Application, End User, and Country-Wise Analysis - Analysis and Forecast, 2021-2031

Published: | BIS Research Inc. | 234 Pages | Delivery time: 1-2 business days

Price

Back to Top
Pharmacogenomics Services Market - A Global and Regional Analysis: Focus on Service, Technology, Application, End User, and Country-Wise Analysis - Analysis and Forecast, 2021-2031
Published: January 7, 2022
BIS Research Inc.
Content info: 234 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

“Global Pharmacogenomics Services Market to Reach $9,346.8 Million by 2031.”

Market Report Coverage - Pharmacogenomics Services

Market Segmentation

  • Service - Genotyping, SNP Identification, Pharmacogenetic Testing, and Other Services
  • Technology - Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other Technologies
  • Application - Oncology, Infectious Disease, Neurology/Psychiatry, Cardiovascular, and Other Applications
  • End User - Research Organizations, Pharmaceutical Companies, Diagnostic Centers, and Other End Users

Regional Segmentation

  • North America - U.S. and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Demark, Netherlands, and Rest-of-Europe
  • Asia-Pacific - Japan, China, Australia, India, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
  • Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
  • Increasing Rate of Adverse Drug Reaction
  • Surge in Usage of Pharmacogenomics for Drug Discovery and Development

Market Challenges

  • Lack of Use of Available Data for Drug Development Initiatives
  • Lack of High Complexity Testing Centers
  • Difficulties in Detecting Gene Variation Affecting Drug Response
  • Regulatory Challenges for Direct-to-Consumer (DTC) Pharmacogenomics Companies

Market Opportunities

  • Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
  • Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
  • Rise of Direct-to-Consumer (DTC) Testing Services

Key Companies Profiled

Abbott Laboratories, Admera Health, LLC, Mesa Laboratories, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd., geneOmbio Technologies Pvt Ltd., Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OmeCare, QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Precipio, 23andMe, Inc., OneOme, LLC, DiaCarta, Inc., OPKO Health.

Key Questions Answered in this Report:

  • How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
  • What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
  • What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
  • How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
  • What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Service (genotyping, SNP identification, pharmacogenetic testing, and other services)
    • Technology (polymerase chain reaction, microarray, sequencing, and other technologies)
    • Application (oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications)
    • End user(research organizations, pharmaceutical companies, diagnostic centers, and other end users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
  • Who are the leading players with significant offerings in the global pharmacogenomics services market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development.

Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Furthermore, companies focus on developing pharmacogenomic tests based on advanced molecular assay technologies, which is expected to further support physicians in offering better informed clinical decisions. The development of advanced pharmacogenomic tests also enables the research community to establish effective strategies for discovering novel biomarkers associated with various diseases, which could be harnessed to develop targeted therapies.

Within the research report, the market is segmented on the basis of service, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence associated with cancer, infectious diseases, and cardiovascular diseases, worldwide has created a buzz among the biotechnology companies to further invest in developing novel pharmacogenomic tests based on molecular technologies for supporting physicians to offer precision care. Due to the expansive service portfolio and massive global presence, Laboratory Corporation of America Holdings has been the leading player in the pharmacogenomics services ecosystem.

On the basis of region, North America holds the largest share of the pharmacogenomics services market due to the presence of market leaders such as Laboratory Corporation of America Holdings, Illumina, Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated in the U.S., coupled with the significant adoption of high-fidelity pharmacogenomic tests for drug discovery and biomarker research. Further, rising fund infusions by the federal organizations coupled with increasing investments for pharmacogenomics development are some of the prominent underlying factors supporting the growth of the North America pharmacogenomics services market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031. This is majorly attributed to the underlying factors such as an increase in healthcare awareness, a steady economy leading to a higher focus on research, and the growth in the adoption of pharmacogenomic tests, among others.

Table of Contents
Product Code: BHP0366SC

Table of Contents

1 Market

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Global Pharmacogenomics Services Market: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
    • 1.3.4 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Market Definition
    • 1.4.2 Emerging Applications of Pharmacogenomics Services
    • 1.4.3 Significant Services in the Pharmacogenomics Ecosystem
    • 1.4.4 Market Footprint and Growth Potential, $Million, 2020-2031
    • 1.4.5 Impact of COVID-19 on the Global Pharmacogenomics Services Market

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S.
  • 2.3 Legal Requirements and Framework in Europe
    • 2.3.1 China
    • 2.3.2 Japan

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Iceberg Analysis - Global Pharmacogenomics Services Market
  • 3.3 Impact Analysis
  • 3.4 Market Drivers
    • 3.4.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
    • 3.4.2 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
    • 3.4.3 Increasing Rate of Adverse Drug Reaction
    • 3.4.4 Surge in Usage of Pharmacogenomics for Drug Discovery and Development
  • 3.5 Market Restraints
    • 3.5.1 Lack of Use of Available Data for Drug Development Initiatives
    • 3.5.2 Lack of High Complexity Testing Centers
    • 3.5.3 Difficulties in Detecting Gene Variation Affecting Drug Response
    • 3.5.4 Regulatory Challenges for Direct-to-Consumer (DTC) Pharmacogenomics Companies
  • 3.6 Market Opportunities
    • 3.6.1 Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
    • 3.6.2 Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
    • 3.6.3 Rise of Direct-to-Consumer (DTC) Testing Services

4 Competitive Landscape

  • 4.1 Overview
  • 4.2 Synergistic Activities
  • 4.3 Product Approvals
  • 4.4 Product Launches
  • 4.5 Business Expansion, Funding, and Reimbursement Activities
  • 4.6 Mergers and Acquisitions
  • 4.7 Market Share Analysis, 2019 and 2020
  • 4.8 Growth Share Analysis
    • 4.8.1 Growth Share Analysis (by Company)
    • 4.8.2 Growth Share Analysis (by Technology)
    • 4.8.3 Growth Share Analysis (by Application)

5 Service, $Million, 2020-2031

  • 5.1 Overview
  • 5.2 Genotyping
  • 5.3 SNP Identification
  • 5.4 Pharmacogenetic Testing
  • 5.5 Other Services

6 Technology, $Million, 2020 - 2031

  • 6.1 Overview
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Microarray
  • 6.4 Sequencing
  • 6.5 Other Technologies

7 Application, $Million, 2020-2031

  • 7.1 Overview
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Neurology/Psychiatry
  • 7.5 Cardiovascular
  • 7.6 Other Applications

8 End User, $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Research Organizations
    • 8.2.1 Global Pharmacogenomics Services Market (Research Organizations, by Service)
  • 8.3 Pharmaceutical Companies
    • 8.3.1 Global Pharmacogenomics Services Market (Pharmaceutical Companies, by Service)
  • 8.4 Diagnostic Centers
    • 8.4.1 Global Pharmacogenomics Services Market (Diagnostic Centers, by Service)
  • 8.5 Other End Users
    • 8.5.1 Global Pharmacogenomics Services Market (Other End Users, by Service)

9 Region, $Million, 2020-2031

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 North America Pharmacogenomics Services Market (by Application)
    • 9.2.4 North America Pharmacogenomics Services Market (by Service)
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Denmark
    • 9.3.7 Netherlands
    • 9.3.8 Rest-of-Europe
    • 9.3.9 Europe Pharmacogenomics Services Market (by Application)
    • 9.3.10 Europe Pharmacogenomics Services Market (by Service)
  • 9.4 Asia-Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 Australia
    • 9.4.4 India
    • 9.4.5 Singapore
    • 9.4.6 Rest-of-Asia-Pacific (RoAPAC)
    • 9.4.7 Asia-Pacific Pharmacogenomics Services Market (by Application)
    • 9.4.8 Asia-Pacific Pharmacogenomics Services Market (by Service)
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest-of-Latin America (RoLA)
    • 9.5.4 Latin America Pharmacogenomics Services Market (by Application)
    • 9.5.5 Latin America Pharmacogenomics Services Market (by Service)
  • 9.6 Rest-of-the-World
    • 9.6.1 Rest-of-the-World Pharmacogenomics Services Market (by Application)
    • 9.6.2 Rest-of-the-World Pharmacogenomics Services Market (by Service)

10 Company Profiles

  • 10.1 Overview
  • 10.2 Abbott Laboratories
    • 10.2.1 Company Overview
    • 10.2.2 Role of Abbott Laboratories in the Global Pharmacogenomics Services Market
    • 10.2.3 Financials
    • 10.2.4 Key Insights about Financial Health of the Company
    • 10.2.5 SWOT Analysis
  • 10.3 Admera Health, LLC
    • 10.3.1 Company Overview
    • 10.3.2 Role of Admera Health, LLC in the Global Pharmacogenomics Services Market
    • 10.3.3 SWOT Analysis
  • 10.4 Mesa Laboratories, Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Role of Mesa Laboratories, Inc. in the Global Pharmacogenomics Services Market
    • 10.4.3 Financials
    • 10.4.4 Key Insights about Financial Health of the Company
    • 10.4.5 SWOT Analysis
  • 10.5 Dynamic DNA Laboratories
    • 10.5.1 Company Overview
    • 10.5.2 Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Services Market
    • 10.5.3 SWOT Analysis
  • 10.6 F. Hoffmann-La Roche Ltd.
    • 10.6.1 Company Overview
    • 10.6.2 Role of F. Hoffmann La-Roche Ltd. in the Global Pharmacogenomics Services Market
    • 10.6.3 Financials
    • 10.6.4 Key Insights about Financial Health of the Company
    • 10.6.5 SWOT Analysis
  • 10.7 geneOmbio Technologies Pvt Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Role of geneOmbio Technologies Pvt Ltd. in the Global Pharmacogenomics Services Market
    • 10.7.3 SWOT Analysis
  • 10.8 Exact Sciences Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Role of Exact Sciences Corporation in the Global Pharmacogenomics Services Market
    • 10.8.3 Financials
    • 10.8.4 Key Insights about Financial Health of the Company
    • 10.8.5 SWOT Analysis
  • 10.9 Illumina, Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Role of Illumina, Inc. in the Global Pharmacogenomics Services Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights about Financial Health of the Company
    • 10.9.5 SWOT Analysis
  • 10.1 Laboratory Corporation of America Holdings
    • 10.10.1 Company Overview
    • 10.10.2 Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Services Market
    • 10.10.3 Financials
    • 10.10.4 SWOT Analysis
  • 10.11 Myriad Genetics, Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Services Market
    • 10.11.3 Financials
    • 10.11.4 Key Insights about Financial Health of the Company
    • 10.11.5 SWOT Analysis
  • 10.12 OmeCare
    • 10.12.1 Company Overview
    • 10.12.2 Role of OmeCare in the Global Pharmacogenomics Services Market
    • 10.12.3 SWOT Analysis
  • 10.13 QIAGEN N.V.
    • 10.13.1 Company Overview
    • 10.13.2 Role of QIAGEN N.V. in the Global Pharmacogenomics Services Market
    • 10.13.3 Financials
    • 10.13.4 Key Insights about Financial Health of the Company
    • 10.13.5 SWOT Analysis
  • 10.14 Quest Diagnostics Incorporated
    • 10.14.1 Company Overview
    • 10.14.2 Role of Quest Diagnostics Incorporated in the Global Pharmacogenomics Services Market
    • 10.14.3 Financials
    • 10.14.4 SWOT Analysis
  • 10.15 Thermo Fisher Scientific Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Services Market
    • 10.15.3 Financials
    • 10.15.4 Key Insights about Financial Health of the Company
    • 10.15.5 SWOT Analysis
  • 10.16 Precipio
    • 10.16.1 Company Overview
    • 10.16.2 Role of Precipio in the Global Pharmacogenomics Services Market
    • 10.16.3 Financials
    • 10.16.4 SWOT Analysis
  • 10.17 23andMe, Inc.
    • 10.17.1 Company Overview
    • 10.17.2 Role of 23andMe, Inc. in the Global Pharmacogenomics Services Market
    • 10.17.3 SWOT Analysis
  • 10.18 OneOme, LLC
    • 10.18.1 Company Overview
    • 10.18.2 Role of OneOme, LLC in the Global Pharmacogenomics Services Market
    • 10.18.3 SWOT Analysis
  • 10.19 DiaCarta, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Role of DiaCarta, Inc. in the Global Pharmacogenomics Services Market
    • 10.19.3 SWOT Analysis
  • 10.2 OPKO Health
    • 10.20.1 Company Overview
    • 10.20.2 Role of OPKO Health in the Global Pharmacogenomics Services Market
    • 10.20.3 Financials
    • 10.20.2 Key Insights About Financial Health of the Company
    • 10.20.3 SWOT Analysis

List of Figures

  • Figure 1: Estimates for Global Healthcare Market, 2018 and 2020
  • Figure 2: Impact Analysis of Market Drivers and Challenges on the Global Pharmacogenomics Services Market
  • Figure 3: Global Pharmacogenomics Services Market (by Service), $Million, 2020 and 2031
  • Figure 4: Global Pharmacogenomics Services Market (by Application), $Million, 2020 and 2031
  • Figure 5: Global Pharmacogenomics Services Market (by Technology), $Million, 2020 and 2031
  • Figure 6: Global Pharmacogenomics Services Market (by End User), $Million, 2020 and 2031
  • Figure 7: Global Pharmacogenomics Services Market Snapshot
  • Figure 8: Global Pharmacogenomics Services Market Segmentation
  • Figure 9: Global Pharmacogenomics Services Market: Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Global Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 14: Global Pharmacogenomics Services Market: COVID-19 Impact Analysis
  • Figure 15: Components Considered for Clinical Evidence as per the IVDR
  • Figure 16: Process of Medical Device Designation by the MHLW and PMDA
  • Figure 17: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 18: Number of Deaths by Different Forms of Cancer, Million, 2020
  • Figure 19: Benefits of Multiplexing Reactions
  • Figure 20: Share of Key Developments and Strategies, January 2018-December 2021
  • Figure 21: Share of Synergistic Activities (by Company), January 2018-December 2021
  • Figure 22: Share of Product Approvals (by Company), January 2018-December 2021
  • Figure 23: Number of Product Launches (by Company), January 2018-December 2021
  • Figure 24: Share of Business Expansion, Funding, and Reimbursement Activities (by Company), January 2018-December 2021
  • Figure 25: Share of Mergers and Acquisitions (by Company), January 2018-December 2021
  • Figure 26: Market Share Analysis for the Global Pharmacogenomics Services Market, $Million, 2019 and 2020
  • Figure 27: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Company), 2020
  • Figure 28: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Technology), 2020-2031
  • Figure 29: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Application), 2020-2031
  • Figure 30: Global Pharmacogenomics Services Market (by Service)
  • Figure 31: Global Pharmacogenomics Services Market (by Service), 2020 and 2031
  • Figure 32: Global Pharmacogenomics Services Market (by Genotyping), $Million, 2020-2031
  • Figure 33: Global Pharmacogenomics Services Market (by SNP Identification), $Million, 2020-2031
  • Figure 34: Global Pharmacogenomics Services Market (by Pharmacogenetic Testing), $Million, 2020-2031
  • Figure 35: Global Pharmacogenomics Services Market (by Other Services), $Million, 2020-2031
  • Figure 36: Global Pharmacogenomics Services Market (by Technology)
  • Figure 37: Global Pharmacogenomics Services Market (by Technology), $Million, 2020 and 2031
  • Figure 38: Global Pharmacogenomics Services Market (by PCR), $Million, 2020-2031
  • Figure 39: Global Pharmacogenomics Services Market (by Microarray), $Million, 2020-2031
  • Figure 40: Evolution of Sequencing for Molecular Diagnostics
  • Figure 41: Global Pharmacogenomics Services Market (by Sequencing), $Million, 2020-2031
  • Figure 42: Global Pharmacogenomics Services Market (by Other Technologies), $Million, 2020-2031
  • Figure 43: Global Pharmacogenomics Services Market (by Application)
  • Figure 44: Global Pharmacogenomics Services Market (by Application), 2020 and 2031
  • Figure 45: Global Pharmacogenomics Services Market (by Oncology), $Million, 2020-2031
  • Figure 46: Global Pharmacogenomics Services Market (by Infectious Diseases), $Million, 2020-2031
  • Figure 47: Global Pharmacogenomics Services Market (by Neurology/Psychiatry), $Million, 2020-2031
  • Figure 48: Global Pharmacogenomics Services Market (by Cardiovascular), $Million, 2020-2031
  • Figure 49: Global Pharmacogenomics Services Market (by Other Applications), $Million, 2020-2031
  • Figure 50: Global Pharmacogenomics Services Market (by End User)
  • Figure 51: Global Pharmacogenomics Services Market (by End User), $Million, 2020-2031
  • Figure 52: Global Pharmacogenomics Services Market (by Research Organizations), $Million, 2020-2031
  • Figure 53: Global Pharmacogenomics Services Market (Research Organizations by Service), Share, 2020 and 2031
  • Figure 54: Global Pharmacogenomics Services Market (by Pharmaceutical Companies), $Million, 2020-2031
  • Figure 55: Global Pharmacogenomics Services Market (Pharmaceutical Companies, by Service), Share, 2020 and 2031
  • Figure 56: Global Pharmacogenomics Services Market (by Diagnostic Centers), $Million, 2020-2031
  • Figure 57: Global Pharmacogenomics Services Market (Diagnostic Centers, by Service), Share, 2020 and 2031
  • Figure 58: Global Pharmacogenomics Services Market (by Other End Users), $Million, 2020-2031
  • Figure 59: Global Pharmacogenomics Services Market (Other End Users, by Service), Share, 2020 and 2031
  • Figure 60: Global Pharmacogenomics Services Market Snapshot (by Region)
  • Figure 61: Global Pharmacogenomics Services Market (by Region), $Million, 2020-2031
  • Figure 62: Global Pharmacogenomics Services Market (by Region), 2020 and 2031
  • Figure 63: North America Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 64: North America Pharmacogenomics Services Market (by Country), $Million, 2020-2031
  • Figure 65: U.S. Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 66: Canada Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 67: North America Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
  • Figure 68: North America Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
  • Figure 69: Europe Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 70: Europe Pharmacogenomics Services Market (by Country), $Million, 2020-2031
  • Figure 71: Germany Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 72: U.K. Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 73: France Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 74: Italy Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 75: Spain Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 76: Denmark Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 77: Netherlands Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 78: Rest-of-Europe Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 79: Europe Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
  • Figure 80: Europe Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
  • Figure 81: Asia-Pacific Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 82: APAC Pharmacogenomics Services Market (by Country), $Million, 2020-2031
  • Figure 83: Japan Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 84: China Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 85: Australia Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 86: India Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 87: Singapore Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 88: Rest-of-Asia-Pacific Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 89: Asia-Pacific Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
  • Figure 90: Asia-Pacific Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
  • Figure 91: Latin America Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 92: Latin America Pharmacogenomics Services Market (by Country), $Million, 2020-2031
  • Figure 93: Brazil Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 94: Mexico Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 95: Rest-of-Latin America Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 96: Latin America Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
  • Figure 97: Latin America Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
  • Figure 98: Rest-of-the-World Pharmacogenomics Services Market, $Million, 2020-2031
  • Figure 99: Rest-of-the-World Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
  • Figure 100: Rest-of-the-World Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
  • Figure 101: Total Number of Companies Profiled
  • Figure 102: Abbott Laboratories: Portfolio
  • Figure 103: Abbott Laboratories: Overall Financials, $Million, 2018-2020
  • Figure 104: Abbott Laboratories: Revenue (by Segment), $Million, 2018-2020
  • Figure 105: Abbott Laboratories: Revenue (by Region), $Million, 2018-2020
  • Figure 106: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020
  • Figure 107: Abbott Laboratories: SWOT Analysis
  • Figure 108: Admera Health, LLC: Portfolio
  • Figure 109: Admera Health, LLC: SWOT Analysis
  • Figure 110: Mesa Laboratories, Inc.: Portfolio
  • Figure 111: Mesa Laboratories, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 112: Mesa Laboratories, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 113: Mesa Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 114: Mesa Laboratories, Inc.: SWOT Analysis
  • Figure 115: Dynamic DNA Laboratories: Portfolio
  • Figure 116: Dynamic DNA Laboratories: SWOT Analysis
  • Figure 117: F. Hoffmann-La Roche Ltd.: Portfolio
  • Figure 118: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020
  • Figure 119: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2018-2020
  • Figure 120: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020
  • Figure 121: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020
  • Figure 122: F. Hoffmann-La Roche Ltd.: SWOT Analysis
  • Figure 123: geneOmbio Technologies Pvt Ltd.: Portfolio
  • Figure 124: geneOmbio Technologies Pvt Ltd.: SWOT Analysis
  • Figure 125: Exact Sciences Corporation: Portfolio
  • Figure 126: Exact Sciences Corporation: Overall Financials, $Million, 2018-2020
  • Figure 127: Exact Sciences Corporation: Revenue (by Segment), $Million, 2018-2020
  • Figure 128: Exact Sciences Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 129: Exact Sciences Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 130: Exact Sciences Corporation: SWOT Analysis
  • Figure 131: Illumina, Inc.: Portfolio
  • Figure 132: Illumina, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 133: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 134: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 135: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 136: Illumina, Inc.: SWOT Analysis
  • Figure 137: Laboratory Corporation of America Holdings: Portfolio
  • Figure 138: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020
  • Figure 139: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
  • Figure 140: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
  • Figure 141: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 142: Myriad Genetics, Inc.: Portfolio
  • Figure 143: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 144: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 145: Myriad Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 146: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 147: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 148: OmeCare: Portfolio
  • Figure 149: OmeCare: SWOT Analysis
  • Figure 150: QIAGEN N.V.: Portfolio
  • Figure 151: QIAGEN N.V.: Overall Financials, $Million, 2018-2020
  • Figure 152: QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
  • Figure 153: QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
  • Figure 154: QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
  • Figure 155: QIAGEN N.V.: SWOT Analysis
  • Figure 156: Quest Diagnostics Incorporated: Portfolio
  • Figure 157: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
  • Figure 158: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2018-2020
  • Figure 159: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 160: Thermo Fisher Scientific Inc.: Portfolio
  • Figure 161: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
  • Figure 162: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 163: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 164: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 165: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 166: Precipio: Portfolio
  • Figure 167: Precipio: Overall Financials, $Million, 2018-2020
  • Figure 168: Precipio: SWOT Analysis
  • Figure 169: 23andMe, Inc.: Portfolio
  • Figure 170: 23andMe, Inc.: SWOT Analysis
  • Figure 171: OneOme, LLC: Portfolio
  • Figure 172: OneOme, LLC: SWOT Analysis
  • Figure 173: DiaCarta, Inc.: Portfolio
  • Figure 174: DiaCarta, Inc.: SWOT Analysis
  • Figure 175: OPKO Health: Portfolio
  • Figure 176: OPKO Health: Overall Financials, $Million, 2018-2020
  • Figure 177: OPKO Health: Revenue (by Segment), $Million, 2018-2020
  • Figure 178: OPKO Health: Revenue (by Region), $Million, 2018-2020
  • Figure 179: OPKO Health: R&D Expenditure, $Million, 2018-2020
  • Figure 180: OPKO Health: SWOT Analysis

List of Tables

  • Table 1: Classification Rules of IVDs under the IVDR
  • Table 2: Registration Criteria for IVD Medical Devices as per the NMPA
  • Table 3: Likert Scale
  • Table 4: Impact Analysis of Market Drivers
  • Table 5: Impact Analysis of Market Restraints
  • Table 6: Examples of Adverse Drug Reactions
  • Table 7: North America: Market Dynamics
  • Table 8: Europe: Market Dynamics
  • Table 9: APAC: Market Dynamics
  • Table 10: Latin America: Market Dynamics